Back to top
more

Trevena (TRVN)

(Delayed Data from NSDQ)

$0.39 USD

0.39
45,364

-0.02 (-4.40%)

Updated Apr 26, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for TRVN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Trevena, Inc. [TRVN]

Reports for Purchase

Showing records 1 - 20 ( 113 total )

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/11/2024

Company Report

Pages: 8

TRV045 Is Worth a Look Given a Differentiated Profile in the Blockbuster S1P Receptor Class

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/31/2023

Company Report

Pages: 5

Inpatient Hurdles Remain but New Real World Data Should Help; Reiterate Buy; Price Target Lowered to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/22/2022

Company Report

Pages: 5

3Q Update; Reiterate Buy; PT to $11

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

08/12/2022

Company Report

Pages: 5

Olinvyk Gets Needed Help with Vizient and Cognition Study; Reiterate Buy Though Lower Target to $1.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

05/12/2022

Company Report

Pages: 4

Olinvyk Still Looking for Its Sea Legs; Reiterate Buy, Target Lowered to $3.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

04/21/2022

Daily Note

Pages: 3

Adding Tiles to Olinvyk''s Data Mosaic; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

04/01/2022

Company Report

Pages: 5

Royalty Financing Demonstrates Needed Patience Is Warranted for Olinvyk

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

02/04/2022

Industry Report

Pages: 10

Rx for Portfolios, Part 3: Commercial Launches Worth Keeping an Eye On

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

12/14/2021

Daily Note

Pages: 3

TRV045 Cleared to Enter the Clinic; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

11/16/2021

Company Report

Pages: 5

Patience is Needed on Olinvyk Launch But New CCO Shows Trevena Is Making the Right Strategic Changes

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

10/01/2021

Daily Note

Pages: 3

TRV027 Shows Promising Efficacy in Small Hospitalized COVID-19 Trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for TRVN

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

08/13/2021

Company Report

Pages: 5

Olinvyk Launch Curve Likely More Elongated Than Expected, But Good Things Come to Those Who Wait; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

05/07/2021

Company Report

Pages: 5

Progress in Formulary Wins as Leading Indicator of Olinvyk Uptake With New Studies Across Portfolio

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

04/22/2021

Daily Note

Pages: 3

TRV027 Selected for REMAP-CAP Study in COVID-19 Patients; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

03/10/2021

Company Report

Pages: 5

Foundations in Place for Olinvyk Launch in a Pandemic Environment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

11/03/2020

Company Report

Pages: 5

The Final Pieces of the Puzzle Fall Into Place as Olinvyk Is Poised for Commercial Launch; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

09/23/2020

Industry Report

Pages: 10

Takeaways From Our Coverage at the 2020 H.C. Wainwright Global Investment Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

09/01/2020

Company Report

Pages: 5

Rags to Riches for Trevena as Olinvyk Launch Nears and Pipeline Looks Ready to Blossom; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Trevena, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

08/11/2020

Company Report

Pages: 5

Olinvyk Is Ready to Go; Reiterate Buy, Raising Target to $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party